Clopidogrel

Clopidogrel, sold as Plavix, is an antiplatelet medicine of the P2Y12 inhibitor class. The US label read lists it to lower the rate of heart attack and stroke for people with acute coronary syndrome (unstable angina or non-ST-elevation heart attack, and ST-elevation heart attack managed medically), and for people with an established peripheral arterial disease, a recent heart attack or a recent stroke. The label carries a boxed warning titled diminished antiplatelet effect in patients with two loss-of-function alleles of the CYP2C19 gene.

Also called Plavix

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 32968. UNII 08I79HTP27 is the UNII of clopidogrel bisulfate, the salt the label names, and is a broad match. The label read is the Sanofi-Aventis U.S. LLC label for Plavix, application NDA020839, effective 2025-05-30 in openFDA. Other clopidogrel labels in openFDA, including generic products and repackagers, were not read. This page records label indications, the title of the boxed warning and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 109 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
109
Phase 3 or 4
91
Recruiting
11
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseRecruitingNot yet recruitingCompletedTerminatedUnknown statusAll statuses
Phase 22090112
Phase 2/3001023
Phase 330191629
Phase 4533531662
No phase101013
All phases11365426109

Conditions these trials study

And 14 more.

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 84 more.

About this drug

Level
Substance
Mechanism
The label says an active metabolite of clopidogrel binds irreversibly to the P2Y12 class of ADP receptors on platelets, which inhibits platelet activation and aggregation.

Classification codes

  • UNII 08I79HTP27

Claims and evidence

Context People for whom the US label of clopidogrel (Plavix) lists an indication: acute coronary syndrome, acute ST-elevation myocardial infarction managed medically, recent myocardial infarction, recent stroke, established peripheral arterial disease

Recipient
Recipient not specified
Population
Patients described in the indications section of the label. The label passages read do not state an age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
Included
  • Patients with acute coronary syndrome without ST-segment elevation (unstable angina or non-ST-elevation myocardial infarction)
  • Patients with acute ST-elevation myocardial infarction who are to be managed medically
  • Patients with established peripheral arterial disease or a history of recent myocardial infarction or recent stroke
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Plavix (clopidogrel), in the Sanofi-Aventis U.S. LLC version dated 2025-05-30 in openFDA, lists the medicine to reduce the rate of myocardial infarction and stroke in patients with acute coronary syndrome without ST-segment elevation (unstable angina or non-ST-elevation myocardial infarction), in patients with acute ST-elevation myocardial infarction who are to be managed medically, and in patients with established peripheral arterial disease or a history of recent myocardial infarction or recent stroke. The label carries a boxed warning titled diminished antiplatelet effect in patients with two loss-of-function alleles of the CYP2C19 gene.

    Applies to Recipient not specified People for whom the US label of clopidogrel (Plavix) lists an indication: acute coronary syndrome, acute ST-elevation myocardial infarction managed medically, recent myocardial infarction, recent stroke, established peripheral arterial disease

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the title of the boxed warning and the mechanism sentence were read; contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (6)
    1. Supports openFDA drug label record for PLAVIX (clopidogrel tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id de8b0b67-eb25-4684-83b5-7ad785314227 (manufacturer Sanofi-Aventis U.S. LLC, application NDA020839), returned on 2026-11-09. The label text is dated 2025-05-30 (effective_time). Other openFDA records of clopidogrel labels, including generic products and repackagers, exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      Label passage quoted in the research quote table (LB-04).
      Retrieved
      Source effective date
      2025-05-30
      Source state
      Current
      Version fingerprint
      5953f77cb9817a2f028855472c54858e95f0a79e190c3f802587c0fd8207371c
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record for PLAVIX (clopidogrel tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id de8b0b67-eb25-4684-83b5-7ad785314227 (manufacturer Sanofi-Aventis U.S. LLC, application NDA020839), returned on 2026-11-09. The label text is dated 2025-05-30 (effective_time). Other openFDA records of clopidogrel labels, including generic products and repackagers, exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1.1 Acute Coronary Syndrome (ACS)
      How it applies
      Label passage quoted in the research quote table (LB-05).
      Retrieved
      Source effective date
      2025-05-30
      Source state
      Current
      Version fingerprint
      5953f77cb9817a2f028855472c54858e95f0a79e190c3f802587c0fd8207371c
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for PLAVIX (clopidogrel tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id de8b0b67-eb25-4684-83b5-7ad785314227 (manufacturer Sanofi-Aventis U.S. LLC, application NDA020839), returned on 2026-11-09. The label text is dated 2025-05-30 (effective_time). Other openFDA records of clopidogrel labels, including generic products and repackagers, exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1.1 Acute Coronary Syndrome (ACS), STEMI sentence
      How it applies
      Label passage quoted in the research quote table (LB-06).
      Retrieved
      Source effective date
      2025-05-30
      Source state
      Current
      Version fingerprint
      5953f77cb9817a2f028855472c54858e95f0a79e190c3f802587c0fd8207371c
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Supports openFDA drug label record for PLAVIX (clopidogrel tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id de8b0b67-eb25-4684-83b5-7ad785314227 (manufacturer Sanofi-Aventis U.S. LLC, application NDA020839), returned on 2026-11-09. The label text is dated 2025-05-30 (effective_time). Other openFDA records of clopidogrel labels, including generic products and repackagers, exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease
      How it applies
      Label passage quoted in the research quote table (LB-07).
      Retrieved
      Source effective date
      2025-05-30
      Source state
      Current
      Version fingerprint
      5953f77cb9817a2f028855472c54858e95f0a79e190c3f802587c0fd8207371c
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    5. Supports openFDA drug label record for PLAVIX (clopidogrel tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id de8b0b67-eb25-4684-83b5-7ad785314227 (manufacturer Sanofi-Aventis U.S. LLC, application NDA020839), returned on 2026-11-09. The label text is dated 2025-05-30 (effective_time). Other openFDA records of clopidogrel labels, including generic products and repackagers, exist and were not used.

      Locator
      results[0].boxed_warning[0], title
      How it applies
      Label passage quoted in the research quote table (LB-08).
      Retrieved
      Source effective date
      2025-05-30
      Source state
      Current
      Version fingerprint
      5953f77cb9817a2f028855472c54858e95f0a79e190c3f802587c0fd8207371c
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    6. Background openFDA drug label record for PLAVIX (clopidogrel tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id de8b0b67-eb25-4684-83b5-7ad785314227 (manufacturer Sanofi-Aventis U.S. LLC, application NDA020839), returned on 2026-11-09. The label text is dated 2025-05-30 (effective_time). Other openFDA records of clopidogrel labels, including generic products and repackagers, exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20250530.
      Retrieved
      Source effective date
      2025-05-30
      Source state
      Current
      Version fingerprint
      5953f77cb9817a2f028855472c54858e95f0a79e190c3f802587c0fd8207371c
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

PLAVIX

No label from the application holder was found in the openFDA label dataset for application NDA020839. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA020839 PLAVIX
  2. Supplemental approval NDA020839 PLAVIX
  3. Supplemental approval NDA020839 PLAVIX
  4. Supplemental approval NDA020839 PLAVIX

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 1

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 3 efficacy supplement approvals on record.

    ProductNDA020839

Registry trials 109

Record details

Record id
cardio:clopidogrel
Content hash
8e607e6e86e22dce3dbc717d293d344c57781197029baf8482e1a487e5fd776d